RSS

Pluristem

The US Food and Drug Administration (FDA) has cleared the expanded access programme (EAP), submitted by Pluristem Therapeutics, for the use of PLX-PAD cell treatment in patients with critical limb ischaemia (CLI). more

News

Developer of placenta-based cell therapy products, Pluristem, has been granted a key US patent by the US Patent and Trademark Office (USPTO) relating to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration. more

News